Across TCGA pan-cancer cohorts, AMTN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AMTN data layer compared with 15 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher AMTN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMTN expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

ACC, LIHC, and LUSC are the cancer types where AMTN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
LIHC	DFS	Median	All	0.118	0.544	.007	9	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
BLCA	DFS	Median	III,IV	1.000	0.430	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AMTN tumor-vs-normal RNA expression · all AMTN data types